Cannabidiol Pharmacotherapy for Comorbid Opioid Addiction and Chronic Pain

大麻二酚药物治疗阿片类药物成瘾和慢性疼痛

• 批准号: 10392326
• 负责人: Joao Paulo De Aquino
• 金额: $ 19.17万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-05-01 至 2026-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10392326
• 关键词: Acute; Adverse effects; Adverse event; Analgesics; Animals; Behavior; Behavioral Paradigm; Biological Markers; Biometry; Brief Pain Inventory; Cannabidiol; Cannabinoids; Clinical; Clinical Research; Clinical Trials; Collaborations; Connecticut; Cues; DSM-V; Data; Development; Dose; Enrollment; Foundations; Goals; Grant; Heroin; Hour; Human; Laboratory Study; Link; Maintenance; Measures; Mentored Patient-Oriented Research Career Development Award; Mentors; Methadone; Methods; Morbidity - disease rate; National Institute of Drug Abuse; Opiate Addiction; Opioid; Opioid agonist; Oral; Outcome; Outcome Study; Pain; Pain Measurement; Pain Research; Pain management; Participant; Patient Self-Report; Patients; Persons; Pharmaceutical Preparations; Pharmacotherapy; Placebo Control; Placebos; Population; Positioning Attribute; Property; Psychiatrist; Questionnaires; Randomized; Relapse; Research; Research Training; Resources; Safety; Self Administration; Sensory; Severities; Sex Differences; Techniques; Testing; Therapeutic; Time; Training; Treatment Efficacy; Urine; Verbal Learning; Visual; Vulnerable Populations; Work; Writing; abuse liability; addiction; behavioral pharmacology; career; chronic pain; cognitive testing; comorbidity; computerized; craving; drug testing; endogenous cannabinoid system; hedonic; indexing; meetings; mortality; multimodality; new therapeutic target; non-cancer chronic pain; novel; novel therapeutics; opioid agonist therapy; opioid treatment program; opioid use; opioid use disorder; overdose death; pain reduction; pain sensitivity; patient population; performance tests; preclinical study; programs; response; responsible research conduct; safety study; skills; symposium; therapeutic biomarker; treatment response

PROJECT SUMMARY/ABSTRACT This proposal seeks to investigate the analgesic and anti-craving efficacy of Cannabidiol (CBD) for comorbid opioid use disorder (OUD) and chronic pain. Chronic pain afflicts approximately 70% of people with OUD. Opioid agonist treatment effectively reduces opioid use overdose deaths, but does not alleviate chronic pain. Convergent preclinical studies have shown that cannabinoids reduce pain sensitivity and opioid-seeking behavior, suggesting they could be leveraged for treatment. Yet, the therapeutic efficacy of cannabinoids for comorbid OUD and chronic pain remains unknown. Given CBD’s lack of hedonic properties and established analgesic and anti-craving effects, it holds particular therapeutic promise for this population. Quantitative Sensory Testing (QST) is a computerized pain assessment method used to reliably measure antinociception and predict the pain treatment response. QST pain biomarkers can be integrated with behavioral paradigms to investigate the two-pronged efficacy of CBD for alleviating pain sensitivity and cue- induced opioid craving. The objective of this proposal is to apply behavioral pharmacology, multimodal pain research and clinical trial methods to study the safety and therapeutic efficacy of CBD for people with comorbid OUD and chronic pain. This will have a significant impact for this patient population, by (i) determining the safety of acute CBD administration (Aim 1); (ii) determining the dose of CBD required to reduce pain sensitivity and cue-induced opioid craving (Aim 2); (iii) understanding the safety of long-term CBD co-administration with opioid agonist maintenance (Aim 3), and (iv) providing preliminary data on the efficacy of CBD to reduce pain severity/interference and opioid craving in the clinical setting (Aim 4). Aims 1 and 2 will be carried out through human laboratory study, and Aims 3 and 4 will be executed through a pilot clinical trial. These studies will serve as the basis for novel treatments and therapeutic biomarkers for comorbid OUD and chronic pain. This proposal will integrate state-of-the-art facilities at Yale and at the VA Connecticut, with established collaborations with local opioid treatment programs. The applicant has assembled a renowned team of expert mentors in the fields of opioid, cannabinoid and pain research. This proposal builds on preliminary work on cannabinoid modulation of pain sensitivity in humans with comorbid OUD and chronic pain. Formal didactics, symposia and national scientific meetings will support the applicant’s training. Specific training goals include developing exceptional skills in (i) behavioral pharmacology of addiction (ii) multimodal assessment of pain, (iii) clinical trials and advanced biostatistics, (iv) grant writing, and (v) responsible conduct of research. Finally, this application leverages the applicant’s robust clinical foundation as a board-certified addiction psychiatrist. The vital support from this K23 award will allow the applicant’s scientific development, leading to an independent research program that timely combines interdisciplinary methods towards developing novel therapeutics for OUD and chronic pain.

项目摘要/摘要 该提案旨在研究大麻二酚（CBD）的镇痛和抗捕获效率 合并症阿片类药物使用障碍（OUD）和慢性疼痛。慢性疼痛遭受约70％的患者 Oud。阿片类药物的治疗有效地减少了阿片类药物的使用过量死亡，但不会减轻慢性 疼痛。收敛性临床前研究表明，大麻素会降低疼痛敏感性和寻求阿片类药物 行为，表明它们可以利用治疗。然而，大麻素的治疗效率 合并的Oud和慢性疼痛仍然未知。鉴于CBD缺乏享乐设施并建立了 镇痛和反捕获作用，它对该人群具有特殊的治疗前景。 定量感觉测试（QST）是一种用于可靠的计算机化疼痛评估方法 测量抗伤害感受并预测疼痛治疗反应。 QST疼痛生物标志物可以与 行为范式研究了CBD的两种良好效率，以减轻疼痛敏感性和提示 诱发阿片类药物的渴望。该建议的目的是应用行为药理学，多模式疼痛 研究和临床试验方法，用于研究CBD的安全性和治疗效率 Oud和慢性疼痛。通过（i）确定该患者人群将对该患者人群产生重大影响 急性CBD管理的安全性（AIM 1）； （ii）确定降低疼痛敏感性所需的CBD剂量 和提示引起的阿片类药物渴望（AIM 2）； （iii）了解与长期CBD共同管理的安全性 阿片类药物激动剂维护（AIM 3）和（iv）提供有关CBD效率的初步数据，以减轻疼痛 在临床环境中的严重性/干扰和阿片类药物的渴望（AIM 4）。目标1和2将通过 人类实验室研究，目标3和4将通过试点临床试验执行。这些研究会 作为合并OUD和慢性疼痛的新型治疗方法和治疗生物标志物的基础。 该建议将与耶鲁大学和弗吉尼亚州的最先进的设施结合在一起，并已建立 与当地阿片类药物治疗计划的合作。申请人组建了一个著名的专家团队 阿片类药物，大麻素和疼痛研究领域的指导者。该提案以初步工作为基础 合并症和慢性疼痛的人类疼痛敏感性的大麻素调节。正式教学学， 研讨会和国家科学会议将支持申请人的培训。具体的培训目标包括 （i）成瘾行为药理学（ii）疼痛的多模式评估，（iii） 临床试验和高级生物统计学，（iv）授予写作，以及（v）负责任的研究。最后，这个 作为董事会认证的成瘾精神病医生，应用程序利用了该应用程序的强大临床基础。这 该K23奖的重要支持将允许申请人的科学发展，从而导致独立 及时结合跨学科方法来开发新疗法的研究计划 Oud和慢性疼痛。